+3,585.7%
ALNY vs GSK
+230.3%
+3,355.4%
-83.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.8% | +0.2% | -1.0% | -0.9% |
| 7D | -3.5% | -3.6% | +0.1% | -1.6% |
| 30D | +18.9% | -5.9% | +24.8% | +22.9% |
| 3M | -13.3% | -4.3% | -9.1% | -11.2% |
| 6M | -20.3% | -10.8% | -9.5% | -15.2% |
| YTD | -35.1% | +1.8% | -36.9% | -36.1% |
| 1Y | -46.5% | +23.5% | -70.0% | -52.9% |
| 3Y | +28.1% | +49.5% | -21.5% | -2.5% |
| 5Y | +36.1% | +49.7% | -13.6% | -1.3% |
| 10Y | +269.7% | +81.9% | +187.8% | +125.3% |
| All | +3,585.7% | +230.3% | +3,355.4% | +1,524.5% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling